NEW YORK (GenomeWeb) – Quidel said today that the US Food and Drug Administration cleared the firm's Solana molecular platform and associated Group A Streptococcus assay.
Solana leverages the helicase-dependent amplification technology that also underpins Quidel's AmpliVue molecular technology. Solana can process up to 12 patient samples in a 30-minute run, saving time for healthcare professionals in moderately complex settings, Quidel said.